Favorable News Coverage Somewhat Unlikely to Impact Ocular Therapeutix (OCUL) Stock Price

News stories about Ocular Therapeutix (NASDAQ:OCUL) have been trending positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Ocular Therapeutix earned a daily sentiment score of 0.28 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 45.1863608611533 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Here are some of the news headlines that may have effected Accern Sentiment Analysis’s rankings:

Shares of Ocular Therapeutix stock opened at $7.04 on Thursday. The firm has a market capitalization of $255.73, a price-to-earnings ratio of -3.20 and a beta of 1.51. Ocular Therapeutix has a 52-week low of $3.30 and a 52-week high of $11.79. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.22 and a current ratio of 3.23.

Ocular Therapeutix (NASDAQ:OCUL) last released its earnings results on Thursday, March 8th. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.14. The company had revenue of $0.50 million during the quarter, compared to the consensus estimate of $0.51 million. Ocular Therapeutix had a negative return on equity of 145.73% and a negative net margin of 3,296.20%. The firm’s quarterly revenue was up .0% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.52) earnings per share. research analysts forecast that Ocular Therapeutix will post -1.91 EPS for the current year.

A number of equities analysts have commented on OCUL shares. BTIG Research raised Ocular Therapeutix from a “neutral” rating to a “buy” rating in a research note on Friday, January 19th. ValuEngine downgraded Ocular Therapeutix from a “sell” rating to a “strong sell” rating in a research report on Friday, February 2nd. Zacks Investment Research upgraded Ocular Therapeutix from a “hold” rating to a “buy” rating and set a $6.50 target price for the company in a research report on Tuesday, March 13th. HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of Ocular Therapeutix in a research report on Friday, March 9th. Finally, Cantor Fitzgerald restated a “buy” rating and set a $22.00 target price on shares of Ocular Therapeutix in a research report on Thursday, March 8th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $11.70.

TRADEMARK VIOLATION NOTICE: “Favorable News Coverage Somewhat Unlikely to Impact Ocular Therapeutix (OCUL) Stock Price” was first published by BBNS and is owned by of BBNS. If you are reading this news story on another website, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The legal version of this news story can be read at https://baseballnewssource.com/2018/03/22/positive-media-coverage-somewhat-unlikely-to-impact-ocular-therapeutix-ocul-share-price/1925231.html.

About Ocular Therapeutix

Ocular Therapeutix, Inc is a biopharmaceutical company focused on the development, manufacturing and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Its lead product candidate, DEXTENZA (dexamethasone insert) for intracanalicular use, has completed Phase III clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery.

Insider Buying and Selling by Quarter for Ocular Therapeutix (NASDAQ:OCUL)

Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Teen Juan Soto Hits Home Run in First At-Bat
Teen Juan Soto Hits Home Run in First At-Bat
Ji-Man Choi Receives Another Chance in Milwaukee
Ji-Man Choi Receives Another Chance in Milwaukee
Marlins vs Dodgers sets a 10-year record in MGM sportsbooks
Marlins vs Dodgers sets a 10-year record in MGM sportsbooks
Strikeouts Once Again Plaguing Cubs
Strikeouts Once Again Plaguing Cubs
Atlanta Braves: A Mix of Young and Old
Atlanta Braves: A Mix of Young and Old
Major League Baseball is Back and Astros Favored to Repeat
Major League Baseball is Back and Astros Favored to Repeat


Leave a Reply

 
© 2006-2018 BBNS.